CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

STAT News
Original article

STAT+: ARPA-H funds biotechs working on custom RNA therapies

Partnershiptri-specific antibodyNeutral
AI Analysis

Summary

Roche has licensed a tri-specific antibody as part of broader biotech funding activity. ARPA-H is funding biotechs developing custom RNA therapies.

Importance:4/10
Sentiment:
0.00
licensingRNA therapyantibodyARPA-H funding
Related Companies

Read the original article

Published by STAT News on September 2, 2026 1:37 PM

Read Original